Oramed Pharmaceuticals (ORMP) Gains from Investment Securities (2022 - 2025)
Oramed Pharmaceuticals (ORMP) posted Gains from Investment Securities of $3.3 million for Q1 2025, down 55.67% on a QoQ basis from $7.6 million in Q4 2024, and up 189.33% year-over-year from $1.2 million in Q1 2024.
Oramed Pharmaceuticals (ORMP) Gains from Investment Securities (2022 - 2025) Analysis & Trends
Oramed Pharmaceuticals' Gains from Investment Securities history runs 4 years deep, the most recent figure standing at $3.3 million for Q1 2025.
- Quarterly Gains from Investment Securities rose 189.33% year-over-year to $3.3 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $14.5 million (up 172.27% YoY) and the FY2025 annual result came in at -$86.1 million, down 1261.42% from the prior year.
- Gains from Investment Securities was $3.3 million for Q1 2025 at Oramed Pharmaceuticals, down from $7.6 million in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $16.6 million in Q3 2024 and bottomed at -$16.2 million in Q4 2023.
- A 4-year average of -$536200.0 and a median of $102000.0 in 2022 frame the typical range for Gains from Investment Securities.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities tumbled 6122.68% — and 2024, when it jumped 2535.77%.
- Oramed Pharmaceuticals' Gains from Investment Securities stood at $269000.0 in 2022, then tumbled by 6122.68% to -$16.2 million in 2023, then surged by 146.62% to $7.6 million in 2024, then tumbled by 55.67% to $3.3 million in 2025.
- Business Quant data shows ORMP's Gains from Investment Securities at $3.3 million in Q1 2025, $7.6 million in Q4 2024, and $16.6 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Oramed Pharmaceuticals | 169.21 Mn | 169.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 3.35 Mn |
| Mar 31, 2025 | 3.35 Mn |
| Dec 31, 2024 | 7.55 Mn |
| Dec 31, 2024 | 7.55 Mn |
| Sep 30, 2024 | 16.58 Mn |
| Sep 30, 2024 | 16.58 Mn |
| Jun 30, 2024 | -12.97 Mn |
| Jun 30, 2024 | -12.97 Mn |
| Mar 31, 2024 | -3.75 Mn |
| Mar 31, 2024 | -3.75 Mn |
| Dec 31, 2023 | -16.20 Mn |
| Dec 31, 2023 | -16.20 Mn |
| Sep 30, 2023 | 629,000.00 |
| Sep 30, 2023 | 629,000.00 |
| Jun 30, 2023 | -755,000.00 |
| Jun 30, 2023 | -755,000.00 |
| Mar 31, 2023 | -65,000.00 |
| Mar 31, 2023 | -65,000.00 |
| Dec 31, 2022 | 269,000.00 |
| Dec 31, 2022 | 269,000.00 |